MedTrace Logo

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

NCT01793818 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-02-10

No results posted yet for this study

Summary

Tat Oyi vaccination on seropositive patients could help their immune system to recognize and neutralize Tat. The neutralization of extra cellular Tat should help the cellular immune response to eliminate HIV-1 infected cells.

Conditions

  • AIDS

Interventions

BIOLOGICAL

Tat Oyi

Three injections in the arm

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    collaborator OTHER

  • BIOSANTECH

    lead INDUSTRY

Principal Investigators

  • Isabelle Ravaux, MD · Assistance Publique Hopitaux De Marseille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01793818 on ClinicalTrials.gov